Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $10.9 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities fell 9556.9% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year decrease of 9092.7%. This contributed to the annual value of $457.7 million for FY2024, which is 10283.47% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Cash from Financing Activities stood at $10.9 million for Q3 2025, which was down 9556.9% from $764000.0 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Cash from Financing Activities' 5-year high stood at $290.9 million during Q3 2022, with a 5-year trough of $108000.0 in Q2 2024.
  • Moreover, its 5-year median value for Cash from Financing Activities was $9.2 million (2025), whereas its average is $60.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 9978.12% in 2021, then skyrocketed by 1520235.29% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Financing Activities (Quarter) stood at $170000.0 in 2021, then surged by 15202.35% to $26.0 million in 2022, then surged by 664.75% to $198.9 million in 2023, then crashed by 82.14% to $35.5 million in 2024, then plummeted by 69.44% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $764000.0 for Q2 2025, and $9.2 million during Q1 2025.